Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro - Wikidata - awgldk - TriplyDB

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

http://www.wikidata.org/entity/Q28276773

about

Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence Improvement of restless legs syndrome by varenicline as antismoking treatment Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.Compromised neuroplasticity in cigarette smokers under nicotine withdrawal is restituted by the nicotinic α4β2-receptor partial agonist varenicline.Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline Varenicline for tobacco dependence: panacea or plight?Varenicline for tobacco dependence.Varenicline for smoking cessation: efficacy, safety, and treatment recommendations Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.Pharmacogenetic Optimization of Smoking Cessation Treatment.Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats.Smoking cessation therapy with varenicline Organic cation transporter variation and response to smoking cessation therapies Preclinical studies of the potent and selective nicotinic α4β2 receptor ligand VMY-2-95 Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys.A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.α6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history.Pharmacotherapy for alcohol use disorder: current and emerging therapies Oral varenicline for smoking cessation.Varenicline for smoking cessation.Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes A preliminary investigation of varenicline for heavy drinking smokers.Varenicline in the treatment of tobacco dependence.Varenicline: progress in smoking cessation treatment.Tobacco smoking cessation management: integrating varenicline in current practice Varenicline improves motor and cognitive symptoms in early Huntington's disease.Smoking cessation guidelines--2008.Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.

P2860

Q26751374-14DDB964-1A17-435F-991E-E90FBA5BB7CE Q27025687-18B1773A-C2AB-443B-8651-10B51867047E Q28541293-1534E9EA-A16B-4EE7-9EB6-9558442D4E83 Q30396291-71C29C25-1CAA-4509-B20C-AAAC8D202D3C Q30475871-C7F58406-4089-4BD1-82CE-4A180BD904BD Q30477421-65C1FF70-F2AC-4AA9-BA6E-16201FFCC3BE Q30502320-4F61961E-C513-4940-8620-455664F3E980 Q33684431-A7C1AF76-3526-47D7-987B-DFC05AF94F34 Q33768017-49E393A8-B310-4BD5-A2A7-4F6187D4645F Q33885925-BD1B02A1-9B51-499B-900C-604202A7B519 Q34157608-9BD7E58B-2F7E-42DF-85CB-E93F62DB9896 Q34190097-5CF6C7BA-1FA6-4293-BB13-966F54B434DA Q34222136-747F13E8-0981-46EB-A282-B8375C2D16E5 Q34231551-E5D2035E-5F21-4E8F-9F8C-360E96E12387 Q34406363-EB70962A-7CB1-48D5-AEE4-8B1D62D583DF Q34542169-C249EAFD-4E8E-4C59-A07C-11FFC09366D7 Q34578989-F2CFED0C-EAA4-4003-AD5E-B2239DB6C532 Q34626130-6708C0A9-7BC8-4814-9796-31B8D84CD4C0 Q34661812-167159DF-4068-43EE-A439-BCEA0C8CFA49 Q34805380-74E90E97-B056-4BC1-A7ED-A68BC278BA51 Q34974830-BD75F001-3DD1-4944-B322-66750C9F5BF1 Q35057548-18C39403-EC09-4E56-A6BB-A4E43F0F4B0B Q35429740-47680525-E490-455C-812B-E5375C34F73C Q35891345-1E04B978-C618-4DD3-86C7-2177AD56E212 Q35972935-E146C67F-E704-471B-A943-9959AF9E438A Q35982285-4A2C505B-603B-474D-A4E9-E249EB29927E Q35991554-391082CA-7CA0-40D9-A5D8-515417E12DEA Q36304857-A5C0369D-1F0B-4D66-99D1-9397987FF4D3 Q36652326-9D8C99D3-7B18-4D0E-8EE3-D750A34E0A46 Q36684437-7E9F33F3-E553-4B65-A94C-538C09A56859 Q36693204-130A7C14-6360-4ACF-B445-216680CC2AF2 Q36730647-3752BBAA-BA9A-4858-8066-892C893FE286 Q36815343-F85F4BB1-34E2-433F-B92D-15D0911B9A04 Q36821304-250DF80E-6641-4459-94B1-1910D524DDB2 Q36842193-27AED483-4763-4121-BBEE-2EABE0D25D91 Q36904915-F7E5F70C-71F9-4144-BB40-01C073013E3B Q37004076-1CCDF781-1FFA-48FD-A61D-5D9F5C941F5B Q37279618-8C10E531-8A66-4C51-A0A7-3C4732B8A286 Q37325535-762B485D-141E-45EF-96D6-2FD86BF501DD Q37409561-E5F381C4-3B2C-4258-BFFE-B3E46BA2ED69

P2860

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

http://www.wikidata.org/entity/Q28276773

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Metabolism and disposition of ...... agonist, in vivo and in vitro

@ast

Metabolism and disposition of ...... agonist, in vivo and in vitro

@en

Metabolism and disposition of ...... agonist, in vivo and in vitro

@nl

type

label

Metabolism and disposition of ...... agonist, in vivo and in vitro

@ast

Metabolism and disposition of ...... agonist, in vivo and in vitro

@en

Metabolism and disposition of ...... agonist, in vivo and in vitro

@nl

prefLabel

Metabolism and disposition of ...... agonist, in vivo and in vitro

@ast

Metabolism and disposition of ...... agonist, in vivo and in vitro

@en

Metabolism and disposition of ...... agonist, in vivo and in vitro

@nl

P1433

Q28276773-6AB9BF5C-A7D6-4ED8-A3F1-79188722614F

P1476

Q28276773-7EE8F4C3-CEC1-4446-903B-8D58ADF17469

P2093

Q28276773-051F1B3B-B6B7-4457-94B6-19DF419B068B

Q28276773-3C4BBB20-DC74-4469-8939-619091F3A7F6

Q28276773-4926F2EB-8917-4167-AFAA-4A2AD72E389F

Q28276773-582A33D4-1A2E-4A94-B922-24C1BD175DE5

Q28276773-5E74F1F4-47D2-46EE-AF49-20343D7C9200

Q28276773-7D6837B7-11E6-4415-9AAD-00EBE43ED337

Q28276773-826BA541-8802-4AD9-9DAA-F5782747EF90

Q28276773-A47B22A4-AD7A-4AB9-B8CD-C296D6913A3D

P304

Q28276773-0FC13E58-C635-45BC-9E67-242FD4D17C6D

P31

Q28276773-69EA50FD-7A3B-44EF-BEF7-B29DB93FE249

P3181

Q28276773-F64C1B66-66A5-4985-A74B-CBF5EDCFF1E9

P356

Q28276773-7BC6F321-622F-43C8-88B2-EA0F88AB96F7

P407

Q28276773-26C675D7-741C-4FAB-A827-E8515BA65FD2

P433

Q28276773-A9ACC7A9-4D70-40A1-A23F-0219D0B31643

P478

Q28276773-E545868F-E2B9-4A5C-9A78-5BC925328BAB

P577

Q28276773-F623AE06-4437-496E-A6E1-093DED96D690

P5875

Q28276773-EC077376-6BA6-4295-B7A3-D9F2C7E65FE3

P698

Q28276773-CF19E680-4E12-4B30-82C0-9BBDEBC9D657

P921

Q28276773-A0173CE8-052C-4075-B72E-ED489AADEBAE

P3181

P356

P1433

Drug Metabolism and Disposition

P1476

Metabolism and disposition of ...... agonist, in vivo and in vitro

@en

P2093

Anne E Reed-Hagen

http://www.w3.org/2001/XMLSchema#string

Beth J Obach

http://www.w3.org/2001/XMLSchema#string

Jotham W Coe

http://www.w3.org/2001/XMLSchema#string

Kathleen S Zandi

http://www.w3.org/2001/XMLSchema#string

R Scott Obach

http://www.w3.org/2001/XMLSchema#string

Sandra Miller

http://www.w3.org/2001/XMLSchema#string

Suzanne S Krueger

http://www.w3.org/2001/XMLSchema#string

Thomas N O'Connell

http://www.w3.org/2001/XMLSchema#string

P304

121-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2226912

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/DMD.105.006767

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237006437

http://www.w3.org/2001/XMLSchema#string

P698

16221753

http://www.w3.org/2001/XMLSchema#string

P921